99 results
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
in the estimates made by the independent parties and by us.
This prospectus and the information incorporated herein by reference contain summaries of certain … and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein
S-8
1ke9tw3v39
26 Mar 24
Registration of securities for employees
5:01pm
S-8
EX-23.2
bfrq472h5 5vfn
26 Mar 24
Registration of securities for employees
5:01pm
8-K
EX-99.1
cyfr7a q7
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K/A
EX-4.1
yf7jr
22 Dec 23
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-1.1
0veaoe
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
1p57 9izgr7
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
nkbjosmdhwp6z 4kg
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.2
3d8fz n2zb
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm